Home / Business / Eye Catching Stocks Gaining Limelight: Microsoft (NASDAQ:MSFT), Galmed Pharmaceuticals (NASDAQ:GLMD), Anthem (NYSE:ANTM)

Eye Catching Stocks Gaining Limelight: Microsoft (NASDAQ:MSFT), Galmed Pharmaceuticals (NASDAQ:GLMD), Anthem (NYSE:ANTM)

Several matter pinch shares of Microsoft Corporation (NASDAQ:MSFT) [Trend Analysis], as shares surging 0.10% to $57.82 with a share volume of 19.82 Million. Case Western Reserve University stated on Thursday the HoloAnatomy app for Microsoft’s HoloLens augmented reality (AR) headset landed first place for the immersive virtual reality and augmented reality category during the 2016 Jackson Hole Wildlife Film Festival Science Media Awards competition. The app beat Google’s Tilt Brush that enables users to paint in 3D and the 20-minute film David Attenborough’s Great Barrier Reef Dive that offers viewers with a 360-degree view of Australia’s landmark.

The HoloAnatomy app enables viewers to examine the organs of a body at their own pace and from any perspective. This is a step up from dissecting dead tissue and viewing 2D illustrations in medical books, transforming medical education using a $3,000 AR-based headset. Microsoft’s device projects holographic objects into the user’s field of view, mixing virtual with physical and essentially enhancing our learning of the human body. The stock is going forward its 52-week low with 37.99% and moving down from its 52-week high price with -1.50%. To have technical analysis views, liquidity ratio of a firm was calculated 2.40 as evaluated with its debt to equity ratio of 0.75. The float short ratio was 0.59%, as compared to sentiment indicator; Short Ratio was 1.57.

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) [Trend Analysis] luring active investment momentum, shares a gain 18.53% to $5.50. Galmed Pharmaceuticals Ltd. (GLMD) released that it has inked an Investigator-Initiated Clinical Trial Contract with the University of California, San Diego, School of Medicine. The proposed study is a Phase I/IIa trial to assess safety, tolerability, efficacy, and pharmacokinetics of AramcholTM in a juvenile population with nonalcoholic fatty liver disease (NAFLD).

The ARTISAN Study is to be led by Dr. Jeffrey Schwimmer, Professor of Clinical Pediatrics at the University. Fatty liver disease in children has been increasingly recognized as an important pediatric health problem. Pediatric NAFLD has some features that are same to adults and several features that are exclusive to children. In the United States, there are an estimated 5 to 8 million children with NAFLD. The prevalence of NAFLD in children across the developed world is 5 to 10%. From a liver standpoint, the major concern is that NAFLD is a risk factor for cirrhosis and liver cancer. Beyond the risk for serious liver problems, children with NAFLD are also at surged risk for other important health problems comprising type 2 diabetes and atherosclerotic heart disease. The total volume of 1.44 Million shares held in the session was surprisingly higher than its average volume of 39.70 shares. EPS anticipates indicating constrictive facts, the current year from sell-side analysts, Price to current year EPS stands at -8.50%, and looking additional price to next year’s EPS is 16.60%.

Shares of Anthem, Inc. (NYSE:ANTM) [Trend Analysis] runs in leading trade, it moving down -0.13% to traded at $128.42. The firm has price volatility of 1.72% for a week and 1.72% for a month. Its beta stands at 0.53 times. Narrow down four to firm performance, its weekly performance was 3.28% and monthly performance was -0.02%. The stock price of ANTM is moving up from its 20 days moving average with 2.42% and isolated negatively from 50 days moving average with -0.20%.


About Gerard Bergeron

Gerard Bergeron covers Bio-pharmacy or healthcare sector Press Releases news updates. He has extensive three year of experience in content writing as freelance writer. He performs analysis of Healthcare Companies and provides worthy information for investor community. He is an experienced writer with a precise grasp of the English language and a clear, compelling writing style.

Check Also

Stocks Retreat on New Development: Deutsche Bank (NYSE:DB), Ingram Micro (NYSE:IM)

Shares of Deutsche Bank AG (NYSE:DB) [Trend Analysis] swings enthusiastically in regular trading session, it a decrease …

Leave a Reply

Your email address will not be published. Required fields are marked *